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Methods for evaluating risks from exposure to
toxic substances for noncancer health end
points (such as birth defects, respiratory
effects, and hepatotoxicity) are based on the
theory that there is a threshold below which
there is negligible risk of adverse health effects
from environmental exposures. At the U.S.
Environmental Protection Agency (U.S. EPA),
this negligible risk is quantified through the
use of reference doses (RfDs) and reference
concentrations (RfCs). The RfD or RfC is
deﬁned as an estimate of daily or continuous
exposure to the human population (including
sensitive subgroups) that is likely to be without
an appreciable risk of deleterious effects during
a lifetime (U.S. EPA 1999a). The value of the
RfD or RfC is derived by determining a point
of departure divided by uncertainty factors
(UFs), which are used to account for uncer-
tainties in the available studies, such as limita-
tions in the database, variability within
humans, and differences in species response
(i.e., animal-to-human extrapolation).
The point of departure in environmental
health risk assessment is meant to represent the
lowest dose within the range of experimental
data. In past practices, the point of departure
was exclusively based on a no-observed-
adverse-effect level (NOAEL) or a lowest-
observed-adverse-affect level (LOAEL), derived
from animal or epidemiologic studies. The
NOAEL is the highest dose for which there are
no observed statistically or biologically signiﬁ-
cant increases in the frequency or severity of
adverse effects between the exposed population
and its control. Similarly, the LOAEL is the
lowest dose at which there are statistically or
biologically significant increases in the fre-
quency or severity of adverse effects between
the exposed population and its appropriate
control group. The NOAEL/LOAEL struc-
ture, however, does not provide sufficient
information to quantify the equivalent risk lev-
els from exposure at the RfD/RfC because
there is no estimated risk at the NOAEL or
LOAEL itself. Several authors have criticized
the use of the NOAEL because of its sensitivity
to sample size, the high sampling variability
from experiment to experiment, and the
inability to use all of the available dose–
response data (Barnes et al. 1995; Crump
1984; Gaylor et al. 1998; Leisenring and Ryan
1992; U.S. EPA 2000a). Leisenring and Ryan
(1992) have shown that average risk levels
associated with the NOAEL may be substan-
tial. The true risk of exposure at the NOAEL
can vary from zero to > 20%, depending on
the end point, spacing of doses, and numbers
of animals used (Leisenring and Ryan 1992).
In many cases, an adverse effect may not be
detected in a critical effect study because of
insufﬁcient statistical power.
Although the NOAEL/LOAEL structure
does not provide sufficient information to
quantify risk levels from exposure (Gaylor
and Kodell 2000), the resulting RfDs and
RfCs are assumed to be equivalent to negligi-
ble or de minimis risks. As a point of compari-
son, the U.S. EPA has deﬁned 1 in 1,000,000
excess cancer risk as a de minimis risk level for
cancer (Caldwell et al. 1998; Clean Air Act
Amendments 1990; Fiori and Meyerhoff
2002; U.S. EPA 1991), although regulatory
actions are sometimes limited to instances
where risk exceeds 1 in 100,000.
Over the past several years, the U.S. EPA
has been in the process of developing the
benchmark dose (BMD), which is derived
from modeling the exposure–response data, as
an alternative to the NOAEL/LOAEL as the
point of departure for noncancer risk assess-
ments. The BMD is the dose that corresponds
to a speciﬁed level of increased response [the
benchmark response (BMR)] compared with
background. This dose is calculated by ﬁtting
a mathematical model to the dose–response
data, which can be continuous or quantal.
The BMD method has several advantages over
the NOAEL/LOAEL method, including mak-
ing better use of dose–response information
and reﬂecting sample size more appropriately
(Barnes et al. 1995; Crump 1995). In single-
chemical hazard assessments, the BMD
allows for consideration of the dose–response
over the entire exposure range, and further-
more, when a dose derived from benchmark
modeling is used as the point of departure,
actual risk levels can be calculated as an alter-
native to the hazard index (which is typically
based on comparisons of human exposures
with an RfD or RfC).
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The U.S. Environmental Protection Agency (U.S. EPA) generally uses reference doses (RfDs) or
reference concentrations (RfCs) to assess risks from exposure to toxic substances for noncancer
health end points. RfDs and RfCs are supposed to represent lifetime inhalation or ingestion expo-
sure with minimal appreciable risk, but they do not include information about the estimated risk
from exposures equal to the RfD/RfC. We used results from benchmark dose modeling
approaches recently adopted for use in developing RfDs/RfCs to estimate the risk levels associated
with exposures at the RfD/RfC. We searched the U.S. EPA Integrated Risk Information System
(IRIS) database and identiﬁed 11 chemicals with oral RfDs and 12 chemicals with inhalation RfCs
that used benchmark dose modeling. For assessments with sufﬁcient model information, we found
that 16 of 21 (76%) of the dose–response models were linear or supralinear. We estimated the risk
from exposures at the established RfDs and RfCs for these chemicals using a linear dose–response
curve to characterize risk below the observed data. Risk estimates ranged from 1 in 10,000 to 5 in
1,000 for exposures at the RfDs, and from 1 in 10,000 to 3 in 1,000 for exposures at the RfCs.
Risk estimates for exposures at the RfD/RfC values derived from sublinear dose–response curves
ranged from 3 in 1,000,000,000 to 8 in 10,000. Twenty-four percent of reference values corre-
sponded to estimated risk levels greater than 1 in 1,000; 10 of 14 assessments had points of depar-
ture greater than the no-observed-adverse-effect levels. For policy development regarding
management of cancer risks, the U.S. EPA often uses 1 in 1,000,000 as a de minimis risk level.
Although noncancer outcomes may in some instances be reversible and considered less severe than
cancer, our ﬁndings call into question the assumption that established RfD and RfC values repre-
sent negligibly small risk levels. Key words: benchmark dose, noncancer, risk assessment. Environ
Health Perspect 111:1318–1325 (2003). doi:10.1289/ehp.6185 available via http://dx.doi.org/
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guidance document on the application of the
BMD approach in determining the point of
departure for all types of health effects data
(U.S. EPA 2000a). Although a BMR of 10%
has most often been used by the U.S. EPA in
its assessments, it is anticipated that 5% or 1%
would be a more appropriate response level for
some end points and designs. Furthermore, in
these draft guidelines, a lower statistical conﬁ-
dence limit on the BMD (BMDL) is speciﬁ-
cally proposed as a replacement for the
NOAEL/LOAEL in setting the point of depar-
ture, which is used to determine acceptable lev-
els of human exposure to environmental
toxicants. A lower conﬁdence limit is placed on
the BMD to obtain a dose (BMDL) that
assures with high conﬁdence (e.g., 95%) that
the BMR is not exceeded (U.S. EPA 2000a).
In addition to ensuring an added measure of
protection, this process rewards better experi-
mental design and procedures that provide
more precise estimates of the BMD.
Most new and revised RfDs and RfCs in
the U.S. EPA Integrated Risk Information
System (IRIS) assessments are based on BMD
modeling. Certain health end points, how-
ever, are not amenable to modeling, and the
NOAEL/LOAEL approach will continue to
be used in some cases (U.S. EPA 2000a). For
this article, we have reviewed and synthesized
currently available risk assessment informa-
tion on the chemicals for which U.S. EPA ref-
erence values are based on BMD modeling.
We estimate the equivalent risk levels
expected from hypothetical human exposures
at established RfD and RfC values using the
BMD dose–response information to investi-
gate whether these levels represent negligible
risks, and to underscore some of the potential
strengths of using benchmark modeling in
environmental health risk assessment.
Methods
We searched the U.S. EPA IRIS database (U.S.
EPA 2000b) to identify the chemicals for
which current regulatory reference values relied
on BMD modeling. We identiﬁed 11 chemi-
cals with RfDs based on oral BMD values, and
12 chemicals with RfCs based on benchmark
concentration (BMC) values. The BMD and
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Table 1. Risk assessment information for chemicals with oral RfDs derived from benchmark modeling.a
NOAEL LOAEL BMD10 BMDL10 BMD05 BMDL05 RfD
Chemical (mg/kg/day) (mg/kg/day) (mg/kg/day) (mg/kg/day) (mg/kg/day) (mg/kg/day) BMD/BMDL UF (mg/kg/day)
Quantal end point
Beryllium and compounds (U.S. EPA 1998a) 0.1 — 1.4 0.46b —— 3.0 300 0.002
Chloroformc (U.S. EPA 2001b) — 15 (12.9ADJ) 1.7 (1.5ADJ) 1.2 (1.0ADJ)b —— 1.4 100 0.01
1,1-Dichloroethylene (U.S. EPA 2002a) 9 14 6.6 4.6b —— 1.4 100 0.05
1,3-Dichloropropene (U.S. EPA 2000c) 2.5 — 5.1 3.4b —— 1.5 100 0.03
Hexachlorocyclopentadiene (U.S. EPA 2001d) — 10 (7ADJ)1 1 6 b —— 1.8 1,000 0.006
Continuous end point
Benzened (U.S. EPA 2003) — 1.2 2.2 1.2b —— 1.8 300 0.004
EGBEe (U.S. EPA 1999b) — 59 — — 7.7HED 5.1HED
b 1.5 10 0.5
Methylmercury (U.S. EPA 2001a) — — — — 1.4–2.6E–03 0.9–1.5E–03b 1.6 10 0.0001
Naphthalenef (U.S. EPA 1998i) 100 (71ADJ)b 200 (143ADJ) 171(122ADJ) 130 (93ADJ) — — — 1.3 3,000 0.02
Phenolg (U.S. EPA 2002c) 60 — 157 93b —— 1.7 300 0.3
Tributyltin oxide (U.S. EPA 1997a) 0.025 — 0.05 0.034b —— 1.5 100 0.0003
Abbreviations: ADJ, adjusted for duration of exposure; BMD10, BMD that equals a BMR of 10%; BMDL10, lower conﬁdence limit on the BMD10; BMD05, BMD that equals a BMR of 5%;
BMDL05, lower conﬁdence limit on BMD05; Cmax, peak blood concentration; EGBE, ethylene glycol monobutyl ether; HED, human dose of an agent that is believed to induce the same
magnitude of toxic effect as the experimental animal species concentration or dose (this adjustment may incorporate toxicokinetic information on the particular agent, if available, or
use a default procedure, such as assuming that daily oral doses experienced for a lifetime are proportional to body weight raised to the 0.75 power). 
aThe reported number of signiﬁcant ﬁgures is not standardized in IRIS. bPoint of departure. cRfD derived from the LOAEL (1,000-fold UF) = 0.01 mg/kg/day; BMD-based RfD (100-fold UF) = 0.01
mg/kg/day. dOral BMDL[ADJ] was derived from the BMCL[ADJ] (8.2 mg/m3) by route-to-route extrapolation with the assumptions that inhalation absorption was 50% and oral absorption was
100% in the dose range near the BMC; BMDL (adjusted for continuous exposure) = (8.2 mg/m3 × 20 m3/day × 0.5)/70 kg = 1.2 mg/kg/day; former RfD derived from the LOAEL (1,000-fold UF) =
0.001. eHED was calculated as follows: using Cmax for 2-butoxyacetic acid as the dose metric, the BMDL05 was determined to be 64 µM; physiologically based pharmacokinetic modeling was
used to “back-calculate” a human equivalent dose of 5.1 mg/kg/day, assuming that rats and humans receive their entire dose of EGBE from drinking water over a 12-hr period each day.
fRfDs were based on the NOAEL and BMD10 values adjusted for duration (e.g., BMD × 5/7 days); the RfD in IRIS is derived from the NOAEL (3,000-fold UF) = 0.02 mg/kg/day; prospective RfD
derived from BMD (3,000-fold UF) = 0.03 mg/kg/day. gBMD was based on a benchmarkresponse of a 1-standard-deviation change from the control mean. 
Table 2. End points and UFs for chemicals with oral RfDs derived from benchmark modeling.
Composite UFa
Chemical Reference End point: quantal or continuous UF Interspecies Intraspecies Subchronic Database ELE
Beryllium and compounds U.S. EPA 1998a Quantal (small intestinal lesions) 300 10 10 — 3 —
Chloroform U.S. EPA 2001b Quantal (fatty cyst formation in liver and elevated  100 10 10 — — —
serum glutamate-pyruvate transaminase)
1,1-Dichloroethylene  U.S. EPA 2002a Quantal [liver toxicity (fatty change)] 100 10 10 — — —
1,3-Dichloropropene U.S. EPA 2000c Quantal (chronic irritation of stomach) 100 10 10 — — —
Hexachlorocyclopentadiene U.S. EPA 2001d Quantal (chronic irritation of stomach)  1,000 10 10 3b 3b —
Benzene U.S. EPA 2003 Continuous (decreased lymphocyte count) 300 — 10 3 3 3
EGBE  U.S. EPA 1999b Continuous (changes in mean corpuscular  10 — 10 — — —
volume)
Methylmercury U.S. EPA 2001a Continuous (developmental neuropsychologic 10 — 10 — — —
impairment)
Naphthalene U.S. EPA 1998i Continuous (decreased mean terminal body  3,000 10 10 10 3 —
weight in males)
Phenol U.S. EPA 2002c Continuous (decreased maternal body 300 10 10 — 3 —
weight gain)
Tributyltin oxide U.S. EPA 1997a Continuous (immunosuppression;  100 10 10 — — —
decrease in IgE titer)
Abbreviations: EGBE, ethylene glycol monobutyl ether; ELE, effect level extrapolation factor. 
aInterspecies extrapolation, intraspecies differences (human variability), subchronic-to-chronic extrapolation, database deficiencies, and ELE. bUFs assigned a value of 101/2 were
rounded to 3.
Article | Reference values and riskBMC values and other risk assessment infor-
mation for these chemicals are presented in
Tables 1–4 (U.S. EPA 1995a, 1995b, 1995c,
1995d, 1997a, 1998a, 1998c, 1998e, 1998g,
1999b, 2000c, 2001a, 2001b, 2001d, 2002a,
2002c, 2002e, 2003). We have included risk
assessment information for naphthalene, a
chemical with an IRIS assessment containing
an established RfD based on a NOAEL (RfD
= 0.02 mg/kg/day) as well as a prospective
RfD based on BMD modeling (RfD = 0.03
mg/kg/day) (U.S. EPA 1998i).
We determined whether the principal study
identiﬁed for each chemical’s IRIS assessment
was derived from quantal (dichotomous) or
continuous critical effect data (Tables 2 and 4).
For compounds with BMD or BMC values
based on quantal data, the BMR is expressed in
terms of a percent increase in risk of adverse
outcome compared with background. For com-
pounds with BMD or BMC values based on
continuous data, the BMR may be expressed as
a percent change in mean response compared
with control (e.g., immunosuppression with
tributyltin oxide) or in terms of a 1 standard
deviation change from the control mean
response (e.g., decreased lymphocyte count
with benzene). The BMR is a response level
used to define a BMD, which is used as the
point of departure, from which an RfD or RfC
can be developed. The BMR is typically set at
the lower end of the range of responses (e.g.,
10% or 5% change) that can be detected exper-
imentally. This can help to avoid uncertainties
associated with low-dose extrapolation using
models that may not reﬂect biologic realities
(Crump 1995).
Using the benchmark modeling informa-
tion described above from the IRIS assessments
of 19 chemicals, we estimated the equivalent
risk levels expected from hypothetical human
exposures at the established RfDs and RfCs.
We also evaluated whether each of the models
used for BMD calculations was linear, sublin-
ear, or supralinear in the observed dose range
(Table 5) [National Research Council (NRC)
2000; U.S. EPA 1995a, 1995b, 1995c, 1995d,
1997b, 1998b, 1998c, 1998d, 1998f, 1998h,
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Table 3. Risk assessment information for chemicals with RfCs derived from benchmark modeling.a
BMC/
Chemical NOAEL LOAEL BMC10 BMCL10 BMCL10[ADJ] BMCL10[HEC] BMC05 BMCL05 BMCL UF RfC
Quantal end point
Antimony trioxideb (U.S. EPA 1995b) 0.51 (0.42HEC)— 1.43 0.87 0.16 0.074c —— 1.6 300 0.0002
1,3-Butadiene (U.S. EPA 2002e) — 2.5 2.25 1.98c —— —— 1.1 1,000 0.002
1,1-Dichloroethylene (U.S. EPA 2002a) 99.2 (17.7HEC) 297.8 (53.2HEC) 59.95 38.9 — 6.9c —— 1.5 30 0.2
1,3-Dichloropropene (U.S. EPA 2000c) 3.7ADJ 14.9ADJ 5.91ADJ — 3.66 0.72c —— 1.6 30 0.02
Methyl methacrylate (U.S. EPA 1998e) 102.4 (18.2ADJ)— 178.7 143 25.6 7.2c — 104.6 1.2 10 0.7
Methylene diphenyl diisocyanate  0.2 (0.036ADJ) 1.0 (0.18ADJ) 0.22ADJ — 0.14 0.06c —— 1.6 100 0.0006
(U.S. EPA 1998g)
Phosphoric acid (U.S. EPA 1995d) 50 (2.7ADJ) 180  150 100 5.4 3.4c 112 64 1.5 300 0.01
1,1,1,2-Tetraﬂuoroethane (U.S. EPA 1995a) 7,450HEC 37,250HEC — 46,000 8,200 8,200c —— — 100 80
Continuous end point
Benzened (U.S. EPA 2003) — 8.7ADJ 43.77 23 8.2c —— — 1.9 300 0.03
Carbon disulﬁdee (U.S. EPA 1995c) 15.9 (5.7ADJ) 39.2 (14.0ADJ)— 55.1 19.7c —— — — 30 0.7
Chromium VI (particulates) (U.S. EPA  — 0.05 0.036 0.016 0.034c —— — 2.3 300 0.0001
1998c)
EGBE (U.S. EPA 1999b) — 150HEC ——— — 530HEC 380HEC
c 1.4 30 13
Abbreviations: ADJ, dose that has been adjusted for duration of exposure; BMC10, BMC that equals a BMR of 10%; BMCL10, lower conﬁdence limit on the BMC10; BMC05, BMC that equals
a BMR of 5%; BMCL05, lower conﬁdence limit on BMC05; HEC, human equivalent concentration [the human concentration (for inhalation exposure) of an agent that is believed to induce the
same magnitude of toxic effect as the experimental animal species concentration or dose; this adjustment may incorporate toxicokinetic information on the particular agent, if available, or
use a default procedure, such as assuming that daily oral doses experienced for a lifetime are proportional to body weight raised to the 0.75 power]; MVh, human ambient default minute
volume; MVho, human occupational default minute volume; RDDR, regional deposited dose ratio (the ratio of the regional deposited dose calculated for a give exposure in the animal
species of interest to the regional deposited dose of the same exposure in a human; this ratio is used to adjust the exposure effect level for interspecies dosimetric differences to derive a
human equivalent concentration for particles). 
aThe reported number of signiﬁcant ﬁgures is not standardized in IRIS. bPoint of departure is the BMCL10[HEC] (BMCL10[HEC] = BMC10[ADJ] × RDDR = 0.074 mg/m3. cPoint of departure. dBMC was
based on a benchmark response of a 1-standard-deviation change from the control mean; the BMCL is the statistical lower bound estimate on the dose corresponding to a 1-standard-
deviation change from control. eBMC is based on an 8-hr time-weighted average occupational exposure; its point of departure is BMCL10[HEC] = 55.1 mg/m3 × (MVho/MVh × 5/7 days) =
19.7 mg/m3. MVho = 10 m3/day; MVh = 20 m3/day.
Table 4. End points and UFs for chemicals with RfCs derived from benchmark modeling.
Composite UFa
Chemical Reference End point: quantal or continuous UF Interspecies Intraspecies Subchronic Database ELE
Antimony trioxide U.S. EPA 1995b Quantal (pulmonary toxicity, chronic 300 3 10 3 3 —
interstitial inﬂammation)
1,3-Butadiene U.S. EPA 2002e Quantal (ovarian atrophy) 1,000 3 10 — 3 10
1,1-Dichloroethylene U.S. EPA 2002a Quantal [liver toxicity (fatty change)] 30 3 10 — — —
1,3-Dichloropropene U.S. EPA 2000c Quantal (hyperplasia of nasal epithelium) 30 3 10 — — —
Methyl methacrylate U.S. EPA 1998e Quantal (degeneration/atrophy of 10 3 3 — — —
olfactory epithelium)
Methylene diphenyl diisocyanate U.S. EPA 1998g Quantal (hyperplasia of the olfactory epithelium) 100 3 10 — 3 —
Phosphoric acid U.S. EPA 1995d Quantal (bronchiolar ﬁbrosis) 300 3 10 10 — —
1,1,1,2-Tetraﬂuoroethane U.S. EPA 1995a Quantal (Leydig cell hyperplasia) 100 3 10 — 3 —
Benzene U.S. EPA 2003 Continuous (decreased lymphocyte count) 300 — 10 3 3 3
Carbon disulﬁde U.S. EPA 1995c Continuous (peripheral nervous system  30 — 3 — 10 —
dysfunction)
Chromium VI (particulates) U.S. EPA 1998c Continuous (lactate dehydrogenase 300 3 10 10 — —
in bronchioalveolar lavage ﬂuid)
EGBE U.S. EPA 1999b Continuous (changes in red blood cell count) 30 — 10 — — 3
Abbreviations: EGBE, ethylene glycol monobutyl ether; ELE, effect level extrapolation factor.
aInterspecies extrapolation, intraspecies differences (human variability), subchronic-to-chronic extrapolation, database deﬁciencies, and ELE.
Article | Castorina and Woodruff1998j, 1999c, 2000d, 2001c, 2001e, 2002b,
2002d]). To estimate the risk level of the
derived RfDs and RfCs, which have a linear or
supralinear dose–response curve at the
BMD/BMC, we assumed that the dose–
response curves for these compounds are linear
at doses below the BMD or BMC (Figure 1).
For two assessments, sufficient information
was not available to determine the shape of the
dose–response curve (carbon disulfide and
1,1,1,2-tetrafluoroethane), and we assumed
linearity [this assumption did not overly bias
our results because linearity or supralinearity
was the shape of the dose–response curve in
approximately three-quarters (16 of 21) of
cases in which the shape of the dose–response
curve was discernable]. This assumption of lin-
earity at the relevant part of the dose–response
curve is necessary to extrapolate equivalent risk
levels from U.S. EPA reference values derived
from BMD modeling, and it is consistent with
methods proposed in the U.S. EPA draft can-
cer risk assessment guidelines (U.S. EPA
1999d). Such risk-level extrapolation is not
possible using the NOAEL/LOAEL approach.
Methods for risk-level estimation varied
between reference values based on quantal end
points and those based on continuous end
points. For BMD/BMC values derived from
quantal critical effect data, we estimated risk
from exposure at concentrations equal to estab-
lished RfD and RfC values by extrapolating
linearly from the point represented by the
BMR at the BMDL/BMCL to the established
RfD and RfC values (Figure 1). We divided
the risk at the BMR by the composite UF for
those BMD models that were linear or supra-
linear. For example, to estimate risk from
exposure to chloroform’s RfC, we divided the
estimated risk level at the point of departure (1
in 10 for BMR = 10%) by the composite UF
of 100, to arrive at a risk of 1 in 1,000. For
BMD/BMC values derived from continuous
critical effect data (normally distributed), a
change in response of 1 standard deviation
from control is considered roughly equivalent
to a 10% increase in risk of adverse response
from exposure (e.g., benzene’s BMR = change
of 1 standard deviation in lymphocyte count
compared with control mean) (U.S. EPA
2000a, 2003). Therefore, when data quality
and distribution allowed, we treated the dose
that resulted in a 1-standard-deviation change
from control as equivalent to BMD10/BMC10
(BMD that equals a BMR of 10%/BMC that
equals a BMR of 10%) values derived from
quantal data. For assessments based on sublin-
ear dose–response curves, we estimated risk of
exposure at the RfD/RfC dose levels by extrap-
olating the BMD model response function to
the RfD/RfC (i.e., using the BMD model, we
estimated risk by putting the exposure equal to
the RfD/RfC in the model).
For all chemicals in our assessment group
with adequate data, we calculated the ratio of
the central estimate (BMD or BMC) to the
lower statistical confidence limit on the
benchmark dose (BMDL) or concentration
(BMCL) (Tables 1 and 3). This ratio (e.g.,
BMD/BMDL) provides a metric to compare
the relative impact on estimated risk levels
resulting from the selection of the BMD/BMC
versus the BMDL/BMCL as the point of
departure. Finally, among the studies that
identified NOAELs, we compared the mod-
eled BMDL and BMCL values with the
empirical NOAELs as a means to investigate
how using BMDL/BMCL values versus
NOAELs compares with previous RfD/RfC
methods based on the NOAEL approach.
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Figure 1. Linear extrapolation of risk from exposure
at the RfD when the RfD is derived from benchmark
modeling of quantal dose–response data. Assuming
the relationship between risk of adverse outcome
and dose is linear at low doses, we estimated risk
from exposure at concentrations equal to estab-
lished RfD and RfC values by extrapolating from the
point represented by the BMR at the BMDL or
BMCL to established RfD and RfC values. POD,
point of departure. 
aFor quantal data, the BMR represents a percentage
increase in risk compared with controls.
Table 5. Fitted BMD models and dose–response curve characterizations for 23 RfD/RfC assessments.
Shape of 
Chemical Reference value End point Fitted modelsa dose–response curve
Antimony trioxide (U.S. EPA 1995b) RfC Quantal Linear and Weibullb Linear
EGBE (U.S. EPA 1999b, 1999c; NTP 1993, 1998) RfC Continuous Power model (k = 0.95) Linear
Methylene diphenyl diisocyanate (U.S. EPA 1998g, 1998h) RfC Quantal Polynomial regression (βi = 0)c Linear
Methylmercury (U.S. EPA 2001a; NRC 2000) RfD Continuous Power model(k = 1)d Linear
Phenol (U.S. EPA 2002c, 2002d) RfD Continuous Polynomial(β2 ≅ 0)e Linear
Phosphoric acid (U.S. EPA 1995d) RfC Quantal Linear and Weibullb Linear
Tributyltin oxide (U.S. EPA 1997a, 1997b) RfD Continuous Polynomial mean response (βi = 0)c Linear
Benzene (U.S. EPA 2003) RfD Continuous Log-linear Supralinear
Benzene RfC Continuous Log-linear Supralinear
Beryllium (U.S. EPA 1998a, 1998b) RfD Quantal Exponential polynomial Supralinear
1,3-Butadiene (U.S. EPA 2002e) RfC Quantal Weibull  Supralinear
Chloroform (U.S. EPA 2001b, 2001c) RfD Quantal Quantal-linear Supralinear
1,1-Dichloroethylene (U.S. EPA 2002a, 2002b) RfD Quantal Gamma  Supralinear
1,1-Dichloroethylene RfC Quantal Quantal-linear Supralinearf
EGBE (U.S. EPA 1999b, 1999c; NTP 1993, 1998) RfD Continuous Power model (k = 0.66) Supralinear
Naphthalene (U.S. EPA 1998i, 1998j) RfD Continuous Polynomial and power Supralinearg
Chromium VI (particulates) (U.S. EPA 1998c, 1998d) RfC Continuous Polynomial mean response Sublinear
1,3-Dichloropropene (U.S. EPA 2000c, 2000d) RfD Quantal Gamma Sublinear
1,3-Dichloropropene RfC Quantal Gamma Sublinear
Hexachlorocyclopentadiene (U.S. EPA 2001d, 2001e) RfD Quantal Log-logistic  Sublinear
Methyl methacrylate (U.S. EPA 1998e, 1998f) RfC Quantal Polynomial mean response Sublinear
Carbon disulﬁde (U.S. EPA 1995c) RfC Continuous Weibull and polynomial NAh
1,1,1,2-Tetraﬂuoroethane (U.S. EPA 1995a) RfC Quantal Weibull and polynomial (multistage) NAh
Abbreviations: EGBE, ethylene glycol monobutyl ether; NA, not available.
aModels were deﬁned for an observed range of experimental data. bBMCs were obtained using both Weibull and linear models; the models gave similar goodness of ﬁt to the data and
BMC estimates. cLinear dose–response curve because assessment is based on a polynomial model with βi = 0 for i > 1. dModel restricted to not allow supralinear forms. eEssentially linear
dose–response curve because squared coefﬁcient term of second-degree polynomial model is insigniﬁcantly small (β2 ≅ 0). fShape of dose–response curve determined supralinear based
on visual inspection; because slope parameter is small, curve approaches linear at low doses. gShape of dose–response curve determined supralinear based on visual inspection; BMD
model response function was not available. hShape of dose–response curve information was not available; assumed linear or supralinear.
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We found that 13 out of 23 (57%) of the
BMD and BMC values were derived from
quantal versus continuous data. A 10% addi-
tional risk or 10% change from control mean
response was selected as the BMR for 17 of the
23 assessments, and a 5% BMR was selected
for 3 of the remaining 6 assessments (Tables 6
and 7) [National Toxicology Program (NTP)
1993; U.S. EPA 1995a, 1995b, 1995c, 1995d,
1997a, 1998a, 1998c, 1998e, 1998g, 1998i,
1999b, 2000c, 2001a, 2001b, 2001d, 2002a,
2002e]. The BMR values for benzene’s BMC
and BMD and for phenol’s BMD were based
on a 1-standard-deviation change in acute lym-
phocyte count and maternal body weight,
respectively, compared with the control mean
(U.S. EPA 2002c, 2003).
Of the 21 BMD and BMC values for
which sufficient dose–response information
was available, we found that 16 (76%) were
derived from dose–response data ﬁtted to lin-
ear or supralinear models in the observed dose
range (Table 5) (NRC 2000; NTP 1993,
1998; U.S. EPA 1995b, 1995d, 1997b,
1998b, 1998c, 1998d, 1998f, 1998h, 1998j,
1999c, 2000c, 2001c, 2001e, 2002b, 2002d,
2002e, 2003). Seven assessments were based
on linear models (two linear models; three
polynomial models with βi ≅ 0 for i > 1; two
power models with k ≅ 1), nine were based on
supralinear models, and five were based on
sublinear models. Sufﬁcient information was
not available to determine the shape of the ﬁt-
ted model for two assessments, carbon disul-
fide and 1,1,1,2-tetrafluoroethane (i.e., the
response function and model parameters were
not provided) (U.S. EPA 1995a, 1995c).
We calculated 17 RfD and RfC equivalent
risk levels (for 14 compounds) assuming linear
dose–response curves. These risk estimates
ranged from 1 in 10,000 to 5 in 1,000 for the
oral route of exposure for compounds with
RfDs based on BMD values, and from 1 in
10,000 to 3 in 1,000 for inhalation for com-
pounds with RfCs based on BMC values
(Tables 6 and 7). Figures 2 and 3 present the
RfD and RfC equivalent risk estimates on a
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Table 6. Estimated risk levels from exposure at the RfD.
Point of departure RfD
Chemical (mg/kg/day) BMR UF (mg/kg/day) Risk estimate End point: quantal or continuous
Beryllium and compounds (U.S. EPA 1998a) 0.46 10% 300 0.002 1 in 10,000 Quantal (small intestinal lesions)
Chloroform (U.S. EPA 2001b) 1.2 10% 100 0.01 1 in 1,000 Quantal (fatty cyst formation in liver and elevated 
serum glutamate-pyruvate transaminase)
1,1-Dichloroethylene (U.S. EPA 2002a) 4.6 10% 100 0.05 1 in 1,000 Quantal [liver toxicity (fatty change)]
1,3-Dichloropropene (U.S. EPA 2000c) 3.4 10% 100 0.03 1 in 100,000a Quantal (chronic irritation of stomach)
Hexachlorocyclopentadiene (U.S. EPA 2001d) 6.0 10% 1,000 0.006 3 in 109a Quantal (chronic irritation of stomach)
Benzeneb (U.S. EPA 2003) 1.2 1 SD 300 0.004 3 in 10,000 Continuous (decreased lymphocyte count)
EGBE (U.S. EPA 1999b; NTP 1993) 5.1 5% 10 0.5 2 in 1,000 Continuous (changes in mean corpuscular volume)
Methylmercuryc (U.S. EPA 2001a) 0.0009 5% 10 0.0001 5 in 1,000 Continuous (developmental neuropsychological 
impairment)
Naphthalened (U.S. EPA 1998i) 93 10% 3,000 0.03  — Continuous (decreased mean terminal body weight)
Phenol (U.S. EPA 2002c) 93 1 SD 300 0.3 3 in 10,000 Continuous (decreased maternal body weight gain)
Tributyltin oxide (U.S. EPA 1997a) 0.03 10% 100 0.0003 1 in 10,000 Continuous (immunosuppression—decrease in
IgE titer)
EGBE, ethylene glycol monobutyl ether.
aBecause IRIS assessment is based on sublinear dose–response curve, linearity was not assumed for low dose extrapolation, and risk estimate was derived from the BMD model
response function. bBMR is expressed in terms of the standard deviation (in the absence of a clear deﬁnition for an adverse effect for this continuous end point, a default BMR of 1-stan-
dard-deviation change from the control mean was selected). This default deﬁnition of a BMR for continuous end points corresponds to an excess risk of approximately 10% for the pro-
portion of individuals below the second percentile (or above the 98th percentile) of the control distribution for normally distributed effects. Benzene’s oral BMDL[ADJ] was derived from
the BMCL[ADJ] (8.2 mg/m3) by route-to-route extrapolation with the assumptions that inhalation absorption was 50% and oral absorption was 100% in the dose range near the BMC. cBMR
represents a 5% increased risk of neuropsychologic impairment compared to background. dInsufﬁcient data available to estimate risk level (i.e., the response function, underlying distri-
bution of the end point, or mean response and standard deviation of the treatment group and controls were not provided). Naphthalene’s RfD in IRIS derived from the NOAEL (3,000-fold
uncertainty factor) = 0.02 mg/kg/day; Tthe prospective RfD derived from the BMD (3,000-fold uncertainty factor) = 0.03 mg/kg/day.
Table 7. Estimated risk levels from exposure at the RfC.
Point of departure RfC
Chemical (mg/m3) BMR UF (mg/m3) Risk estimate End point: quantal or continuous
Antimony trioxide (U.S. EPA 1995b) 0.074 10% 300 0.0002 3 in 10,000 Quantal (pulmonary toxicity, chronic interstitial
inﬂammation)
1,3-Butadiene (U.S. EPA 2002e) 1.98 10% 1,000 0.002 1 in 10,000 Quantal (ovarian atrophy)
1,1-Dichloroethylene (U.S. EPA 2002a) 6.9 10% 30 0.2 3 in 1,000 Quantal [liver toxicity (fatty change)]
1,3-Dichloropropene (U.S. EPA 2002c) 0.72 10% 30 0.02 3 in 106a Quantal (hyperplasia of nasal epithelium)
Methyl methacrylate (U.S. EPA 1998e) 7.2 10% 10 0.7 8 in 10,000a Quantal (degeneration/atropy of olfactory 
epithelium)
Methylene diphenyl diisocyanate (U.S. EPA 1998g) 0.06 10% 100 0.0006 1 in 1,000 Quantal (hyperplasia of the olfactory epithelium)
Phosphoric acid (U.S. EPA 1995d) 3.4 10% 300 0.01 3 in 10,000 Quantal (bronchiolar ﬁbrosis)
1,1,1,2-Tetraﬂuoroethane (U.S. EPA 1995a) 8,200 10% 100 80 1 in 1,000 Quantal (Leydig cell hyperplasia)
Benzeneb (U.S. EPA 2003) 8.2 1 SD 300 0.03 3 in 10,000 Continuous (decreased lymphocyte count)
Carbon disulﬁdec (U.S. EPA 1995c) 19.7 10%  30 0.7 3 in 1,000 Continuous (peripheral nervous system 
dysfunction)
Chromium VI (particulates)d (U.S. EPA 1998c) 0.034 10% 300 0.0001 — Continuous (lactate dehydrogenase in 
bronchioalveolar lavage ﬂuid)
EGBE (U.S. EPA 1999b; NTP 1993) 380 5% 30 13 2 in 1,000 Continuous (changes in red blood cell count)
EGBE, ethylene glycol monobutyl ether.
aBecause IRIS assessment is based on sublinear dose–response curve, linearity was not assumed for low dose extrapolation, and risk estimate was derived from the BMC model
response function. bBMC was based on a BMR of 1-standard-deviation change from the control mean (in the absence of a clear deﬁnition for an adverse effect for this continuous end
point, a default BMR of 1-standard-deviation change from the control mean was selected). This default deﬁnition of a BMR for continuous end points corresponds to an excess risk of
approximately 10% for the proportion of individuals below the second percentile (or above the 98th percentile) of the control distribution for normally distributed effects. cA 10% relative
change was selected as an appropriate BMR for the nerve conduction velocity measurements because this level is about equal to a difference of 1 standard deviation from the control,
and because a change of about 10% would likely raise concern in a clinical setting. dInsufﬁcient data available to estimate risk level (i.e., the response function, underlying distribution
of the end point, or mean response and standard deviation of the treatment group and controls were not provided).
Article | Castorina and Woodrufflogarithmic scale for these chemicals with lin-
ear or supralinear dose–response curves at the
BMD/BMC. For four RfD and RfC equiva-
lent risk levels (for 3 compounds), we used the
sublinear dose–response model to calculate
risk at the RfD or RfC. These risk estimates
ranged from 3 in 1,000,000,000 to 1 in
100,000 from the oral route of exposure for
compounds with RfDs based on BMD values,
and from 3 in 1,000,000 to 8 in 10,000 from
inhalation for compounds with RfCs based on
BMC values (Tables 6 and 7).
Five of 21 reference values (24%) reviewed
for this assessment corresponded to estimated
risk levels greater than 1 in 1,000. Insufﬁcient
information was available to estimate risk
from exposure at two reference values that
were based on continuous response data,
chromium VI particulates and naphthalene
(i.e., the response function, underlying distrib-
ution of the end point, or mean response and
standard deviation of the treatment group and
controls were not provided). Figure 4 presents
the distribution of estimated risk levels from
human exposures at established RfD and RfC
values for compounds with a linear or supra-
linear dose–response curve at the BMD. Risk
estimates for four assessments derived from
sublinear dose–response curves are presented
in Tables 6 and 7.
Among the chemicals for which the RfD
was based on a BMD, the BMD/BMDL ratio
ranged from 1.3 to 3.0. Among the chemicals
for which the RfC was based on a BMC, the
BMC/BMCL ratio ranged from 1.1 to 2.3
(Tables 1 and 3). Thus, using the central esti-
mate of the BMD or BMC (maximum likeli-
hood estimate) instead of the lower statistical
confidence limit (BMDL or BMCL) as the
point of departure would result in a 1- to
3-fold difference in the estimated risk levels
(Figures 2 and 3).
The effect level extrapolation factor (ELE)
is an UF analogous to the LOAEL-to-
NOAEL extrapolation factor. ELEs were
applied in the assessments of three com-
pounds, 1,3-butadiene (RfC), benzene (RfC
and RfD), and ethylene glycol monobutyl
ether (RfC) (Tables 2 and 4) (U.S. EPA
1999b, 2002e, 2003). Thus, no ELE factor
was assigned for 16 of 17 assessments that
were based on a BMR of 10%.
When we compared the points of depar-
ture (i.e., BMDL/BMCL values) with the
NOAELs, we found that the points of depar-
ture were higher than the NOAELs in 10 of
the 14 studies with identified NOAELs
(Figure 5). The BMDL values were up to 4.6
times higher than the empirical NOAELs
(range, 0.5–4.6), and the BMCL values were
up to 3.9 times higher than the empirical
NOAELs (range, 0.2–3.9) (Tables 1 and 3).
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Figure 2. Estimated risk levels from exposure at the RfD based on the BMD and the BMDL derived from linear
or supralinear dose–response curves. EGBE, ethylene glycol monobutyl ether. 
Figure 3. Estimated risk levels from exposure at the RfC based on the BMC and the BMCL derived from linear
or supralinear dose–response curves. EGBE, ethylene glycol monobutyl ether. 
aBMC central estimate not provided by the U.S. EPA.
Figure 4. Distribution of estimated risk levels from
human exposures at established RfD and RfC val-
ues for reference doses derived from linear or
supralinear dose–response curves. 
aRisk estimates for assessments based on sublinear
dose–response curves are not included.
Figure 5. Ratio of the points of departure (PODs) to
empirically derived NOAELs. PODs based on bench-
mark modeling. 
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Discussion
To determine whether U.S. EPA reference val-
ues represent negligibly small risk levels, we
reviewed and synthesized currently available
risk assessment information on chemicals for
which established RfD and RfC values are
based on BMD modeling. For RfDs and RfCs
derived from linear or supralinear dose–
response curves, our risk estimates ranged
from 1 in 10,000 to 5 in 1,000 for the oral
route of exposure, and from 1 in 10,000 to 3
in 1,000 for inhalation. Risk estimates for
RfDs and RfCs derived from sublinear
dose–response curves ranged from 3 in
1,000,000,000 to 8 in 10,000. Twenty-four
percent of reference values reviewed for this
assessment corresponded to estimated risk lev-
els greater than 1 in 1,000. The estimated risk
of exposure to 1,1-dichloroethylene at its RfC,
for example, corresponded to a 3-in-1,000 risk
of adverse effect [liver toxicity (fatty change)].
The BMD methodology is the ﬁrst step in
the development of continuous risk functions
that can be used to estimate risks at different
exposures rather than using an RfD/RfC
approach, which has limited use in the deci-
sion-making process. For example, BMD and
BMC values that are based on the same level
of adverse response (e.g., BMR = 10%) can be
used to rank the potential hazard of exposure
to multiple toxicants. Further application of
BMD models, such as has been done here,
can be used for estimating adverse noncancer
health outcomes from different exposures for
other risk-ranking exercises, regulatory policy
development, and cost/beneﬁt analyses.
The U.S. EPA used a variety of fitted
models to calculate the BMD/BMC values
found in IRIS (e.g., K power, linear, quantal-
linear, exponential polynomial, and Weibull).
To compare RfD and RfC equivalent risk lev-
els, we assumed that the dose–response curves
for the chemicals in our assessment group are
linear at doses below the point of departure.
This assumption could have resulted in both
underestimates and overestimates of risk. In
the case of a supralinear dose–response curve
at low doses, for example, this assumption
may have resulted in an underestimate of risk.
Among the chemicals we reviewed, 9 of the
21 assessments with sufﬁcient information to
determine the shape of the dose–response
curve were based on supralinear functions. In
the case of a sublinear dose–response, this
assumption may have resulted in a marked
overestimate of risk. For the 5 assessments
based on sublinear dose–response curves,
therefore, we did not assume linearity for low
dose extrapolation and risk estimation.
We believe that the assumption of linear-
ity in the relevant part of the dose–response
curve is justified and useful to compare risk
levels among this group of compounds.
Seventy-six percent of BMD and BMC values
considered in this assessment were derived
from dose–response data fitted to linear or
supralinear models. Furthermore, the range of
extrapolation for the RfD/RfC calculations
was not large among this group, with most
based on points of departure extrapolated to 2
orders of magnitude or less (7 were extrapo-
lated to 1 order of magnitude, 13 were extrap-
olated to 2 orders of magnitude, and 3 were
extrapolated to 3 orders of magnitude). The
average and median composite UFs among
the compounds in our assessment are 340 and
100, respectively. This implies that even if the
dose–response curve for a particular com-
pound is not strictly linear at much lower
doses, we could expect the potential impact on
the risk estimate to be relatively small.
Current U.S. EPA methodology for refer-
ence value derivation assumes that the estab-
lished RfDs/RfCs represent negligibly small
risk levels. For assessments that have linear
dose–response curves, the extrapolation from
the point of departure is typically 2 orders of
magnitude or less. Therefore, for the RfD/RfC
values to represent risk levels that are below
regulatory concern, the dose–response curve
would have to drop off sharply after the point
of departure. This assumption seems unlikely,
especially given our ﬁnding that a large number
of the assessments we reviewed (9 of 21) were
based on supralinear dose–response functions.
Although this supralinearity may carry signiﬁ-
cant implications for risk assessment, more
research is needed to determine whether these
dose–response relationships remain supralinear
at very low doses. On the other hand, assess-
ments based on dose–response curves that are
not monotonic may have sublinear or stepwise
relationships below the observed data.
Using the BMDL or BMCL as the point of
departure in the risk assessment of noncarcino-
genic compounds rather than the BMD or
BMC central estimate is generally characterized
as a conservative assumption (in the health-pro-
tective sense). We found that using the central
estimate of the BMD (maximum likelihood
estimate) instead of the lower bound estimate as
the point of departure results in a 1- to 3-fold
difference in the risk estimates. According to
the U.S. EPA draft BMD guidelines (U.S.
EPA 2000a), a lower conﬁdence limit is placed
on the BMD to obtain a dose (BMDL) that
assures with high conﬁdence (e.g., 95%) that
the BMR is not exceeded. This process of
using the BMDL rewards better experimental
design and procedures that provide more pre-
cise estimates of the BMD, resulting in
tighter conﬁdence intervals and thus BMDLs
that are closer to the central estimate. Our
results suggest that the current practice of
using the statistical lower bound estimate ver-
sus the maximum likelihood estimate as the
point of departure is reasonable and does not
substantially bias the risk estimate.
For carcinogens, the U.S. EPA typically
develops a linear estimate of the slope of the
dose–response curve, under the assumption
that the curve is linear at low doses. This
allows for quantification of risk at any given
level of exposure. The U.S. EPA has deﬁned
1 in 1,000,000 excess cancer risk as a de min-
imis risk level for cancer (Caldwell et al. 1998;
Clean Air Act Amendments 1990; Fiori and
Meyerhoff 2002; U.S. EPA 1991), although
regulatory actions are sometimes limited to
instances where risk exceeds 1 in 100,000.
Among compounds in IRIS with RfDs and
RfCs based on BMD modeling, however, we
found risk estimates as great as 5 in 1,000.
Although noncancer outcomes may in some
instances be reversible and considered less
severe, this finding calls into question the
assumption that noncancer RfD and RfC val-
ues represent “acceptable levels” of exposure.
In addition, some of the noncancer health end
points considered in this assessment are severe
and irreversible events, for example, ovarian
atrophy (1,3-butadiene) and developmental
neuropsychologic impairment (methylmer-
cury), highlighting the need for a renewed dis-
cussion within the public health community
about what should be considered an “accept-
able level” of risk from exposure to toxicants
with noncancer health end points.
Most of the BMDLs and BMCLs used as
points of departure in IRIS are based on 10%
BMRs, many with values higher than the
empirically derived NOAELs. This research
should help inform discussions about whether
this level of BMR is adequately protective of
the public health, and whether human expo-
sures at concentrations equal to the resulting
reference values do in fact represent negligibly
small risk levels.
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